Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Cancers (Basel). 2021 May 12;13(10):2312. doi: 10.3390/cancers13102312.
Cancers (Basel). 2021.
PMID: 34065877
Free PMC article.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M, Stege H, Pemler S, Heinz J, Fleischer MI, Graf C, Ruf W, Loquai C, Grabbe S.
Haist M, et al. Among authors: fleischer mi.
Cancers (Basel). 2021 Oct 12;13(20):5103. doi: 10.3390/cancers13205103.
Cancers (Basel). 2021.
PMID: 34680252
Free PMC article.
Item in Clipboard
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
Haist M, Stege H, Ebner R, Fleischer MI, Loquai C, Grabbe S.
Haist M, et al. Among authors: fleischer mi.
Cancers (Basel). 2022 Apr 21;14(9):2082. doi: 10.3390/cancers14092082.
Cancers (Basel). 2022.
PMID: 35565212
Free PMC article.
Item in Clipboard
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, Becker JC, Meissner M, Kleeman J, Pföhler C, Hassel J, Grabbe S, Loquai C.
Stege HM, et al. Among authors: fleischer mi.
Cancer Immunol Immunother. 2021 Nov;70(11):3313-3322. doi: 10.1007/s00262-021-02925-4. Epub 2021 Apr 18.
Cancer Immunol Immunother. 2021.
PMID: 33870464
Free PMC article.
Item in Clipboard
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA, Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L.
Knispel S, et al. Among authors: fleischer mi.
Eur J Cancer. 2021 May;148:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15.
Eur J Cancer. 2021.
PMID: 33735811
Item in Clipboard
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, Meier F, Göppner D, Herbst RA, Zillikens D, Terheyden P.
Sadik CD, et al. Among authors: fleischer mi.
Front Immunol. 2021 Feb 23;11:588582. doi: 10.3389/fimmu.2020.588582. eCollection 2020.
Front Immunol. 2021.
PMID: 33708189
Free PMC article.
Item in Clipboard
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation.
Fleischer MI, Röhrig N, Raker VK, Springer J, Becker D, Ritz S, Bros M, Stege H, Haist M, Grabbe S, Haub J, Becker C, Reyda S, Disse J, Schmidt T, Mahnke K, Weiler H, Ruf W, Steinbrink K.
Fleischer MI, et al.
J Thromb Haemost. 2022 Dec;20(12):2823-2836. doi: 10.1111/jth.15894. Epub 2022 Oct 12.
J Thromb Haemost. 2022.
PMID: 36161697
Free article.
Item in Clipboard
Cite
Cite